Kenta Biotech is a company focused on the discovery and development of fully human monoclonal antibodies for the treatment of life threatening hospital acquired infections.
Nosocomial Infections
Pipeline
Products in Clinical Development
Products in Preclinical Development
Kenta's lead product targets nosocomial infections with a high medical need
»
imprint
PIPELINE
Under the strategic agreement with Kenta Biotech, Aridis Pharmaceuticals (USA) has acquired the entire Kenta mAb Portfolio.
